Sanofi stock: Nov. 24 investor event follows two drug approvals
Published on 11/22/2026 at 18:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSInvestors watch approvals and guidance
- Sanofi is scheduled to attend the Leerink Partners East Coast bus tour in Boston on November 24, 2026.
- VaxRabeo received European approval for all ages on November 19.
- Third-quarter sales rose 14.3% at constant exchange rates, and Sanofi upgraded its 2026 outlook.
Sanofi stock heads into the week of November 23 with a scheduled investor appearance and two recent regulatory approvals. Sanofi's investor calendar lists the Leerink Partners East Coast (POLARxPRESS) Bus Tour in Boston for Tuesday, November 24, with Manuela Buxo, executive vice president and head of Specialty Care, as speaker. The Sanofi investor calendar provides the event details.
Recent approvals support the outlook
The event follows Sanofi's announcement on November 19 that the European Union approved its next-generation rabies vaccine, VaxRabeo, for all ages. On November 18, the US Food and Drug Administration approved Infilbray for neurological manifestations of Type 3 Gaucher disease in adults and children weighing at least 15 kilograms. Both decisions expand the company's commercial and specialty-care backdrop ahead of the investor meeting.
Sanofi's latest reported quarter provides the financial context. In its October 30 release, the company reported third-quarter sales of 14,444 million euros, up 14.3% at constant exchange rates. Business earnings per share reached 3.55 euros, an increase of 19.6% at constant exchange rates, while full-year 2026 sales guidance was upgraded to low-teens growth at constant exchange rates. The third-quarter results release sets out the figures and guidance.
Sanofi stock traded at 84.77 euros on Lang & Schwarz at 18:16 CET on Sunday, November 22. The quote gives investors a weekend reference ahead of the Boston appearance, while the company's upgraded sales and business EPS outlook remains the central financial context.
Sanofi investor facts
- Company: Sanofi S.A.
- ISIN: FR0000120578
- Scheduled event: Leerink Partners East Coast (POLARxPRESS) Bus Tour, November 24, 2026, Boston
- Latest reported quarter: Q3 2026 sales of 14,444 million euros
- Lang & Schwarz quote: 84.77 euros on November 22, 2026 at 18:16 CET
The broader French market can be followed through the CAC 40 market coverage.
